{
  "id": "5027b419f9179cd0",
  "title": "AI At The FDA Legal Implications And Strategic Considerations For Drug Developers",
  "description": "20260119T110000Z",
  "content": "",
  "source": "clinicalleader.com",
  "source_url": "https://www.clinicalleader.com/doc/ai-at-the-fda-legal-implications-and-strategic-considerations-for-drug-developers-0001",
  "published_at": "20260119T110000Z",
  "fetched_at": "2026-01-20T00:23:08.181708+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda",
    "drug",
    "ai"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.clinicalleader.com/doc/ai-at-the-fda-legal-implications-and-strategic-considerations-for-drug-developers-0001",
    "url_mobile": "",
    "title": "AI At The FDA Legal Implications And Strategic Considerations For Drug Developers",
    "seendate": "20260119T110000Z",
    "socialimage": "https://vertassets.blob.core.windows.net/image/1bbad86d/1bbad86d-66e1-494a-a644-85d97f00dde7/intellectual_property_ethical_gettyimages_1974055076.jpg",
    "domain": "clinicalleader.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}